The Academy of Managed Care Pharmacy (AMCP) thanks the Pharmacy Quality Alliance (PQA) for the opportunity to provide comments in response to the Call for Comments on PQA Endorsement Consideration of Two New Performance Measures.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to submit comments for the record on the 21st Century Cures Act as revised in November 2016. AMCP supports the need for timelier and more proactive communications between biopharmaceutical manufacturers and population health decision makers.
Consistent with established guidelines, we are writing to request a meeting with OMB/OIRA staff to discuss the impact of the final rule for SAMHSA- 4162-20: Confidentiality of Substance Use Disorder Patient Records. The modification of the federal regulations governing the confidentiality of drug and alcohol treatment and prevention records, 42 CFR Part 2 (Part 2), is a priority for the Academy of Managed Care Pharmacy (AMCP).
The Academy of Managed Care Pharmacy (AMCP) thanks the U.S. Pharmacopeial Convention (USP) for the opportunity to provide comments on the Draft Medicare Model Guidelines v7.0 as published on the USP website on October 1, 2016. AMCP and its members have been involved with the Medicare Model Guidelines since the inception of the process and appreciate USP’s willingness to receive input from the affected health care sectors.
The Academy of Managed Care Pharmacy (AMCP) acknowledges that abuse deterrent opioid analgesic drug products are appropriate for certain patients. However, we are opposed to House Bill 1698 because it would mandate coverage for these products on every formulary, and restrict a health insurance plan’s ability to use utilization review requirements to determine the appropriate use of these products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments on the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years 2018 through 2022 as published in the Federal Register on September 13, 2016. These written comments are provided in addition to the oral comments AMCP will present at the public meeting on October 20, 2016.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the draft scoping document that will examine the clinical effectiveness and value of abuse-deterrent formulation (ADF) of opioids in pain management released on September 8, 2016. AMCP appreciates the broad input from payers as well as patients, pain management specialists, and pharmaceutical manufacturers.